Featured Articles
-
Insights Into GMP Manufacturing Of RNA-LNP Drug Products
2/29/2024
Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and strategic collaborations.
-
Developing A Comprehensive Regulatory Approach For LNP Drugs
2/26/2024
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.
-
The Key To Accelerating RNA-LNP Drug Development
12/27/2023
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Optimized And Scalable LNP Composition For RNA Vaccine Delivery
12/20/2023
Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.
-
Trends In Next-Generation Delivery Technologies
11/22/2023
Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.
-
Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy
11/22/2023
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
-
How To Improve Lentivirus Polishing Recovery
10/25/2023
Explore how we used capture with weak anion exchange and optimized the Capto™ Core 700 chromatography resin polishing step to maximize infectious recovery.
-
How To Develop A Scalable AAV Process, From Start To Finish
10/24/2023
Get highlights from a developed process that has been – and continues to be refined – by Cytiva scientists. These insights are framed around common challenges in AAV development and production.
-
Recommendations For Successful IND Approval Of RNA-LNP Drugs
8/22/2023
The existing regulatory system is ambiguous for RNA therapeutics. Leverage this Investigational New Drug (IND) guide to help accelerate and strengthen the process IND filing of novel nanomedicines.
-
Lowering The Lipid Barrier To RNA-LNP Therapeutics
8/22/2023
Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.